Trial Profile
An open-label, randomized, two-treatment, two period crossover, single-dose study to determine the relative bioavailability of fixed combination of final market image aliskiren/valsartan 75/160 mg tablets and the free combination of aliskiren 75 mg and valsartan 160 mg in healthy subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Aliskiren/valsartan (Primary) ; Aliskiren; Valsartan
- Indications Diabetes mellitus; Heart failure; Hypertension; Myocardial ischaemia
- Focus Pharmacokinetics
- Sponsors Novartis
- 21 Jun 2007 Status change from in progress to completed
- 01 Feb 2007 New trial record.